Corona Remedies Limited Share Price & Stock Analysis

Corona Remedies Limited (NSE: CORONA, BSE: 544644) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹14,481 Cr, it ranks #474 by market cap among the 6,197 Indian listed companies on FinBizNet, and #10 of 63 in Pharmaceuticals. At ₹2,335.00 (as of 16 Nov 2026), the share price is 14.1% below its 52-week high of ₹2,719.30 and 74.7% above its 52-week low of ₹1,336.60.

Key Metrics

Current Price₹2,335.00
Market Cap₹14,481 Cr
NSE SymbolCORONA
BSE Code544644
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Pharmaceuticals
P/E Ratio77.6
Return on Equity24.79%
Return on Assets14.99%
52-Week Range₹1,336.60 – ₹2,719.30
3-Month Price Change+10.2%
Beta (1Y)0.08
Dividend Yield0.43%
HeadquartersAhmedabad, Gujarat
Websitewww.coronaremedies.com

Latest Quarterly Results — Q2 FY27

Revenue₹441 Cr
Net Profit₹60 Cr
Net Margin13.7%
EPS (Basic)₹9.86
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Corona Remedies Limited Quarterly Revenue and Profit Trend

Corona Remedies Limited reported revenue of ₹441 Cr in Q2 FY27, up 22.2% from ₹361 Cr in Q2 FY26 and up 4.4% from ₹422 Cr in Q1 FY27. It posted a net profit of ₹60 Cr for the quarter, against a net profit of ₹52 Cr in Q2 FY26 (up 15.3%). Across the 5 quarters from Q2 FY26 to Q2 FY27, quarterly revenue ranged from ₹342 Cr (Q3 FY26) to ₹441 Cr (Q2 FY27). The company was profitable in each of these 5 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹441 Cr₹60 Cr13.7%
Q1 FY27₹422 Cr₹60 Cr14.2%
Q4 FY26₹353 Cr₹45 Cr12.8%
Q3 FY26₹342 Cr₹41 Cr12.1%
Q2 FY26₹361 Cr₹52 Cr14.5%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 69.00% of Corona Remedies Limited's shares as of Sept 2026, unchanged from Dec 2025. Delivery averaged 44.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Corona Remedies Limited

CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.

Products and Services

1. Pharmaceuticals-This segment develops, manufactures, and markets products in women’s healthcare, cardio-diabeto, pain management, urology, and other areas, such as vitamin minerals and nutrients, and gastrointestinal and respiratory therapies. 2. NA-NA 3. NA-NA 4. NA-NA

Business Segments

1. Pharmaceuticals-100%

Corona Remedies Limited vs Peers — Pharmaceuticals

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Abbott India Ltd.₹56,531 Cr36.334.46%₹1,814 Cr-8.1%
Emcure Pharmaceuticals Ltd₹42,344 Cr47.919.57%₹2,820 Cr+73.3%
Ajanta Pharma Limited₹41,474 Cr39.425.39%₹1,794 Cr+27.8%
Piramal Pharma Ltd₹32,600 Crn/m-4.00%₹2,617 Cr+22.8%
RUBICON RESEARCH LIMITED₹28,526 Cr112.319.14%₹576 Cr+162.7%
Caplin Point Laboratories Ltdte₹18,155 Cr28.319.94%₹630 Cr+23.6%
Pfizer Ltd.₹17,811 Cr24.517.16%₹727 Cr-24.2%
Eris Lifesciences Ltd₹17,691 Cr28.318.07%₹892 Cr-17.5%
Corona Remedies Limited₹14,481 Cr77.624.79%₹441 Cr—

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Corona Remedies Limited?

Corona Remedies Limited is trading at ₹2,335.00, with a market capitalisation of ₹14,481 Cr.

Which sector does Corona Remedies Limited belong to?

Corona Remedies Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).

What are the key financial ratios of Corona Remedies Limited?

Corona Remedies Limited has a P/E of 77.6 and a return on equity of 24.79%.

What is the stock symbol of Corona Remedies Limited?

Corona Remedies Limited is listed on the NSE under the symbol CORONA and on the BSE under the scrip code 544644.

What were Corona Remedies Limited's latest quarterly results?

In Q2 FY27, Corona Remedies Limited reported revenue of ₹441 Cr and net profit of ₹60 Cr, with basic EPS of ₹9.86 (consolidated, parsed from the company's exchange filing).

How have Corona Remedies Limited's revenue and profit changed over the past year?

Corona Remedies Limited reported revenue of ₹441 Cr in Q2 FY27, up 22.2% from ₹361 Cr in Q2 FY26 and up 4.4% from ₹422 Cr in Q1 FY27.

What is the promoter holding in Corona Remedies Limited?

Promoters held 69.00% of Corona Remedies Limited's shares as of Sept 2026, unchanged from Dec 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.